Decoy Therapeutics Inc. (DCOY)
NASDAQ: DCOY · Real-Time Price · USD
0.8290
-0.0348 (-4.03%)
At close: Jan 29, 2026, 4:00 PM EST
0.8283
-0.0007 (-0.08%)
After-hours: Jan 29, 2026, 4:38 PM EST
Decoy Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
2
Market Cap
5.25M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 1.84M | -3.39M | -64.84% |
| Dec 31, 2020 | 5.23M | 1.77M | 51.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| GeoVax Labs | 3.35M |
| Xenetic Biosciences | 2.86M |
| Cyclerion Therapeutics | 2.86M |
| Can-Fite BioPharma | 560.00K |
| Aprea Therapeutics | 488.24K |
| Abpro Holdings | 183.00K |
| VivoSim Labs | 140.00K |
DCOY News
- 16 days ago - Decoy Therapeutics Reaches Global Access Commitment Agreement to Focus on Development of a Globally Accessible, Scalable Peptide-Conjugate Manufacturing Platform - PRNewsWire
- 22 days ago - Salarius Pharmaceuticals Changes Corporate Name to Decoy Therapeutics and Nasdaq Ticker Symbol to DCOY Reflecting Focus on Next-Generation Peptide Conjugate Therapeutics - GlobeNewsWire
- 5 weeks ago - Salarius Pharmaceuticals Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting - GlobeNewsWire
- 6 weeks ago - Salarius Pharmaceuticals Announces Planned Corporate Name and Ticker Symbol Change to Decoy Therapeutics, Reflecting Strategic Pivot to Next-Generation Antiviral and Peptide-Conjugate Platform - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals to Collaborate with Texas Biomedical Research Institute on Avian Flu Study - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Cites Errors on S&P CapIQ Platform Following Merger with Decoy Therapeutics, Affirms Its Shares Continue to Trade on the Nasdaq Stock Market Under the Symbol “SLRX” - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals and Decoy Therapeutics Complete Merger - GlobeNewsWire
- 2 months ago - Salarius Pharmaceuticals Announces Pricing of $7 Million Underwritten Public Offering - PRNewsWire